Sign inJoin waitlistJoin the waitlist

Renier Brentjens

Deputy Director and Chair of Medicine · University at Buffalo School of Medicine

Credentials: · · ·

History

Department of Medicine · University of Pennsylvania Health System
Present
Department of Medicine · University at Buffalo School of Medicine
Present
University at Buffalo School of Medicine
Present

Weill Cornell Medical College
1998–2002
Hematology and Medical Oncology
Memorial Sloan Kettering Cancer Center
1998–2002
Yale-New Haven Hospital
1996–1998
University at Buffalo
Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo
1992–1996
Allergy and Immunology
University at Buffalo School of Medicine
1994–1996
Davidson College
1989

Research

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
New England Journal of Medicine · 2018 · 2,239 citations
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia
Science Translational Medicine · 2014 · 2,062 citations
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia
Science Translational Medicine · 2013 · First of 25 authors · Corresponding · 1,696 citations

JP
Jae Park
32 papers · 3 as a fellow
KC
Kevin Curran
21 papers
Marco Davila
18 papers · 1 as a fellow
Craig Sauter
15 papers
SG
Sergio Giralt
15 papers
AD
Anthony Daniyan
13 papers · 3 as a fellow
DS
David Scheinberg
10 papers
Lia Palomba
9 papers
MG
Mark Geyer
9 papers · 4 as a fellow
MP
Miguel-Angel Perales
9 papers
Bianca Santomasso
8 papers
EM
Elena Mead
8 papers

Grants

Optimizing Dual-Targeted and Dual-Armored CAR T Cells for Small Cell LungCancer
National Cancer Institute · U01
Contact PI · $3.2M · Roswell Park Cancer Institute Corp
2021–2027
The Memorial Sloan Kettering Cancer Center SPORE in Leukemia
National Cancer Institute · P50
Project lead · $1.7M · Sloan-Kettering Inst Can Research
2021–2026
MSK Paul Calabresi Career Development Award for Clinical Oncology
National Cancer Institute · K12
PI · $3.7M · Sloan-Kettering Inst Can Research
2015–2025
MSK SPORE in Lymphoma
National Cancer Institute · P50
Project lead · $1.6M · Sloan-Kettering Inst Can Research
2016–2022

Clinical trials

Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2009–2016
Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
Principal investigator · Completed · Phase 1
Memorial Sloan Kettering Cancer Center
2009–2014
Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer
Principal investigator · Completed · Phase 1, Phase 2
Memorial Sloan Kettering Cancer Center
2005–2014
Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2005–2016